CELZ Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Creative Medical Technology Holdings, Inc. had $0.0M of revenue in fiscal 2025, down 45.5% on the year before. Over five years, revenue changed β48.4% a year on average.
Last close Β· Oct 23, 2026
$0.74
4.4%Hi! I read Creative Medical Technology Holdings, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β45.5%
No. Sales fell 45.5% last year.
Does it make a profit?
β99,916.7%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Creative Medical Technology Holdings, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 6, 2026
Friday Β· in 12 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 7, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 8, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 20, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 7, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 8, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 9, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 14, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 8, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Creative Medical Technology Holdings, Inc. had $0.0M of revenue in fiscal 2025, down 45.5% on the year before. Over five years, revenue changed β48.4% a year on average. Its operating margin was β102,380.0%, down 50,162.7Β pts: of every 100 in sales, about β102,380 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Creative Medical Technology Holdings, Inc. lost $6.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Creative Medical Technology Holdings, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 61.0%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Creative Medical Technology Holdings, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $10.7M | $8.3M | $3.5M | $5.9M | $7.2M |
| Interest coverage | β0.7x | β | β | β | β |
| Current ratio | 10.2x | 5.6x | 27.7x | 18.7x | 26.0x |
| Quick ratio | 10.2x | 5.6x | 27.6x | 18.7x | 26.0x |
| Total assets | $11.3M | $19.2M | $10.7M | $6.7M | $7.8M |
| Total liabilities | $1.1M | $3.3M | $0.4M | $0.3M | $0.3M |
| Shareholders' equity | $10.2M | $15.9M | $10.3M | $6.3M | $7.5M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Creative Medical Technology Holdings, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 5 / 8 | 4 / 8 | 1 / 8 | 4 / 8 | 2 / 8 | 3 / 8 | 2 / 8 | 4 / 8 |
| Accruals ratio | β99.5% | β673.3% | β3,705.2% | β1,442.6% | β5,748.9% | 357.5% | β15.4% | 18.3% | β2.2% | β1.9% |
| Altman Z'' | β28.64 | β172.98 | β190.48 | β277.45 | β661.98 | 1.36 | β2.44 | 13.80 | β11.32 | β1.08 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.1M | $0.2M | $0.2M | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Net interest income | β | β | β | β | $0.0M | $0.0M | β | β | β | β |
| Gross profit | $0.0M | β$0.0M | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Research and development | $0.1M | $0.3M | $0.1M | $0.0M | $0.0M | $0.1M | $6.3M | $2.0M | $2.4M | $2.3M |
| Operating income | β$0.8M | β$1.2M | β$1.1M | β$1.1M | β$1.1M | β$3.1M | β$10.2M | β$5.6M | β$5.7M | β$6.1M |
| Interest expense | $0.0M | $0.4M | $1.4M | $1.9M | $1.2M | $4.3M | $0.0M | β | β | β |
| Pretax income | β | β$2.7M | β$13.7M | β$8.5M | β$36.3M | $19.2M | β$10.1M | β$5.3M | β$5.5M | β$6.0M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$0.8M | β$2.7M | β$13.7M | β$8.5M | β$36.3M | $19.2M | β$10.1M | β$5.3M | β$5.5M | β$6.0M |
| Net income to common | β | β | β | β | β | $19.2M | β | β | β | β |
| Diluted EPS | β$0.01 | β$0.03 | β$3.50 | β$0.82 | β$62.69 | $5.61 | β$0.93 | β$3.76 | β$3.71 | β$2.52 |
| Diluted shares | 0.09B | 0.11B | 0.00B | 0.01B | 0.29B | 0.00B | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$0.4M | β$0.9M | β$1.1M | β$1.2M | β$0.4M | β$2.2M | β$7.8M | β$8.0M | β$5.3M | β$5.9M |
| Depreciation and amortization | β | β | β | β | β | β | β | $0.1M | $0.1M | β |
| Stock-based compensation | $0.0M | $0.1M | $0.0M | $0.0M | $0.2M | $0.6M | $0.1M | $0.0M | $0.0M | $0.0M |
| Share buybacks | β | β | β | β | β | β | $0.0M | $0.3M | $0.2M | $0.0M |
| Dividends and buybacks | β | β | β | β | β | β | $0.0M | $0.3M | $0.2M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.2M | $0.0M | $0.3M | $0.1M | $0.1M | $10.7M | $8.3M | $3.5M | $5.9M | $7.2M |
| Total debt | β | $0.5M | β | β | β | β | β | β | β | β |
| Current assets | $0.2M | $0.0M | $0.3M | $0.1M | $0.1M | $10.7M | $18.7M | $10.3M | $6.1M | $7.4M |
| Current liabilities | $0.5M | $2.4M | $4.5M | $8.6M | $40.5M | $1.1M | $3.3M | $0.4M | $0.3M | $0.3M |
| Inventory | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Intangible assets | $0.1M | $0.2M | $0.2M | $0.4M | $0.6M | $0.5M | $0.4M | $0.4M | $0.5M | $0.4M |
| Total assets | $0.3M | $0.2M | $0.5M | $0.5M | $0.7M | $11.3M | $19.2M | $10.7M | $6.7M | $7.8M |
| Total liabilities | $0.5M | $2.4M | $4.5M | $8.6M | $40.5M | $1.1M | $3.3M | $0.4M | $0.3M | $0.3M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$0.2M | β$2.2M | β$4.0M | β$8.1M | β$39.8M | $10.2M | $15.9M | $10.3M | $6.3M | $7.5M |
| Margins | ||||||||||
| Gross margin | β | β66.7% | 43.4% | 72.5% | 69.2% | 45.3% | 67.8% | 60.0% | 60.0% | 63.3% |
| Operating margin | β | β24,537.5% | β895.7% | β682.9% | β677.7% | β3,560.3% | β11,562.5% | β62,445.6% | β52,217.3% | β102,380.0% |
| EBITDA margin | β | β | β | β | β | β | β | β61,823.3% | β51,708.2% | β |
| Net margin | β | β55,397.9% | β10,977.3% | β5,126.1% | β22,082.2% | 21,881.3% | β11,449.2% | β58,740.0% | β49,940.9% | β99,916.7% |
| Net interest share of revenue | β | β | β | β | 0.0% | 0.0% | β | β | β | β |
| Returns | ||||||||||
| Return on capital employed | 578.2% | 52.8% | 27.9% | 14.0% | 2.8% | β30.6% | β64.6% | β54.3% | β90.6% | β81.6% |
| Return on equity | β | β | β | β | β | β | β77.8% | β40.3% | β65.8% | β86.5% |
| Return on assets | β237.6% | β1,011.8% | β4,014.6% | β1,683.3% | β5,818.5% | 320.6% | β66.6% | β35.4% | β63.2% | β82.8% |
| Return on tangible equity | β | β | β | β | β | 198.3% | β65.7% | β53.4% | β94.5% | β84.3% |
| Growth | ||||||||||
| Revenue growth | β | β | 2,491.7% | 33.0% | β0.6% | β46.6% | 0.9% | β89.8% | 22.2% | β45.5% |
| Net income growth | β | β | β | β | β | β | β152.8% | β | β | β |
| EPS growth | β | β | β | β | β | β | β116.6% | β | β | β |
| Share count change | β | 13.1% | β96.3% | 164.8% | 2,701.2% | β98.9% | 236.5% | β87.1% | 5.2% | 61.0% |
| Financial health | ||||||||||
| Interest coverage | β118.7x | β3.1x | β0.8x | β0.6x | β0.9x | β0.7x | β | β | β | β |
| Current ratio | 0.5x | 0.0x | 0.1x | 0.0x | 0.0x | 10.2x | 5.6x | 27.7x | 18.7x | 26.0x |
| Quick ratio | 0.5x | 0.0x | 0.1x | 0.0x | 0.0x | 10.2x | 5.6x | 27.6x | 18.7x | 26.0x |
| Capital allocation | ||||||||||
| Stock comp / revenue | β | 3,004.2% | 1.5% | 0.0% | 103.5% | 678.1% | 77.5% | 406.7% | 332.7% | 58.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 5.0 | 4.0 | 1.0 | 4.0 | 2.0 | 3.0 | 2.0 | 4.0 |
| Altman Z'' | β28.6 | β173.0 | β190.5 | β277.5 | β662.0 | 1.4 | β2.4 | 13.8 | β11.3 | β1.1 |
| Accruals ratio | β99.5% | β673.3% | β3,705.2% | β1,442.6% | β5,748.9% | 357.5% | β15.4% | 18.3% | β2.2% | β1.9% |
Source: SEC EDGAR XBRL filings (CIK 0001187953). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
